Table III.

Subgroup analyses.

	No. of patients	mPFS	95% CI	P-value	mOS	95% CI	p-value
KPS, %
>70	28	5.0	3.8–6.2	0.72	10	5.3–14.7	0.22
<70	12	4.0	0–10.8		8	3.8–12.2
MGMT methylation
Yes	20	6.0	3.0–8.9	0.004	10	6.5–13.5	<0.0001
No	16	3.0	2.5–3.5		4	2.2–5.8
IDH mutation
Yes	11	4.0	2.4–5.6	0.94	10	6.4–13.6	0.91
No	16	3.0	1.3–4.7		10	4.4–15.6
Induction phase completed
Yes	27	6.0	4.1–7.9	0.02	10	8.8–11.2	0.004
No	13	3.0	1.7–4.3		4	2.2–5.8
RT ar recurrence
Yes	17	5.0	2.9–7.1	0.48	10	3.7–6.3	0.11
No	23	3.5	2.5–4.5		5	0.11
Surgery at recurrence
Yes	25	6.0	0.1–11.9	0.18	9	5.6 12.4	0.95
No	15	5.0	3.9–6.1		9	2–16

CI, confidence interval; mPFS, median progression-free survival; mOS, median overall survival; KPS, Karnofsky performance status; MGMT, O⁶-methylguanine-DNA methyltransferase; IDH, isocitrate dehydrogenase; RT, radiotherapy.